Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti–Programmed Cell Death Protein 1 in SCLC

Journal of Thoracic Oncology 2026

View at publisher

Authors: Akito Fukuda, Tomoyo Fukami, Kotaro Nomura, Jumpei Kashima, Shogo Kumagai, Yasushi Goto, Yasushi Yatabe, Tatsuya Yoshida

DOI: 10.1016/j.jtho.2026.103693

Cited by: 2

References: 10

Fields of Study & Subjects

Lung Cancer Research Studies Cancer Immunotherapy and Biomarkers vaccines and immunoinformatics approaches

References 10